Press Release (ePRNews.com) - NEW ROCHELLE, N.Y. - Jun 02, 2017 - The advantages of continuous glucose monitoring (CGM) for obtaining real-time blood glucose measurements and its ability to detect and even predict hypo- and hyperglycemic events make it a very useful tool for evaluating experimental glucose-lowering drugs and new approaches for treating diabetes. The current challenges for using CGM in clinical research and specific recommendations for how to optimize the use of CGM and the data collected in clinical trials are explored in an article in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com/). The article is available free on the DTT website (http://online.liebertpub.com/doi/full/10.1089/dia.2017.0054) until July 2, 2017.
The article entitled “Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting (http://online.liebertpub.com/doi/full/10.1089/dia.2017.0054)” is coauthored by Oliver Schnell, Forschergruppe Diabetes, Munich, Germany, Philip Home, Newcastle University, Newcastle upon Tyne, U.K., and an international team of researchers.
CGM offers the opportunity to improve self-management of glycemic control, especially for individuals who are at higher risk of hypoglycemia. Among the researchers’ recommendations is the need to for better standardization of CGM.
“Use of Continuous Glucose Monitoring is increasing significantly in insulin-requiring patients along with a broader use in clinical trials,” says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver (Aurora).
About the Journal
Diabetes Technology & Therapeutics (DTT) (http://www.liebertpub.com/dtt) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) (http://www.liebertpub.com/) website. DTT is the official journal of the International Conference on Advanced Technologies & Treatments for Diabetes.
The International Conference on Advanced Technologies & Treatments for Diabetes (http://www.attd2017.com/) (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world’s leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News ), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Mary Ann Liebert, Inc., publishers